Johnson Fistel, PLLP is investigating Beta Bionics for potential securities law violations related to possibly misleading statements about the company's growth and new patient starts. The probe follows Beta Bionics' disclosure of slower growth in new patient starts for Q4 2025, which fell short of analyst expectations and showed a significant slowdown from previous quarters. This investigation could impact investors who suffered losses based on the company's public statements. Investors affected are encouraged to contact Johnson Fistel to explore their legal options.
Quaker Houghton is set to report quarterly earnings with analysts expecting $1.66 EPS on $504.63 million revenue, signaling a year-over-year earnings decline despite higher sales. The company declared a $0.53 per share dividend, marking its 17th cons...
GraniteShares has announced the weekly distribution amounts for its YieldBOOST ETFs, including COYY, TSYY, NVYY, and others, with distribution rates ranging from about 2% to over 95%. These ETFs use a strategy involving selling put options to generat...
The U.S. Small Business Administration (SBA) announced five finalists for the Freedom 250 Patriot Pitch Competition, celebrating small businesses that used SBA capital to innovate and grow. The finalists—Compotech, Plas-Tech Tooling, Red River, VetPo...
Pixalate's June 2026 OpenEPG™ Index reveals that on large screens (CTV), NBA's Hardwood Classics and Food Network shows dominated programmatic ad spending, with Reality, News, and Sport genres making up 81% of the spend. On small screens (mobile), na...
Vertiv, a key AI infrastructure company, reported strong Q2 2026 results with 24.1% revenue growth and $1.52 adjusted EPS, beating estimates. Despite this, its stock fell over 27% in the past month due to volatility and concerns over sales sustainabi...
